Jeremy WheelerFounder

United Kingdom - Edinburgh, Scotland

Jeremy Wheeler is a medtech executive and company builder with over 30 years’ experience taking regulated healthcare technologies from early concept through scale-up, international expansion, and exit. His background is operational, with deep expertise in quality systems, regulatory strategy, manufacturing, and global supply chains across the UK, Europe, the US, and Asia.

His career has repeatedly centred on inflection points: founding and shaping early-stage companies, professionalising organisations operating under regulatory constraint, and supporting leadership teams through growth, complexity, and strategic transition. He has led businesses from zero infrastructure to commercial maturity, overseen international operations, managed acquisitions and integrations, and worked closely with boards, investors, and acquirers across multiple funding and exit processes.

Jeremy is currently Co-Founder and Chief Executive Officer of BIOCAPTIVA, a biotechnology company addressing a fundamental bottleneck in liquid biopsy and molecular diagnostics: pre-analytics. The company is developing a polymer-based platform for the direct capture of cell-free nucleic acids from biological fluids, with the objective of improving sensitivity, reproducibility, and scalability in downstream diagnostic workflows. His role today is focused on stewardship — setting strategy, building durable teams, embedding quality and regulatory foundations early, and forming long-term partnerships with industry leaders.

Alongside executive roles, Jeremy has served as an investor, non-executive director, and advisor to early and growth-stage healthcare companies. He is particularly effective where boards require pragmatic operational judgement, regulatory fluency, and an ability to bridge scientific ambition, commercial reality, and governance responsibility. His contribution is grounded in experience and pattern recognition, bringing a calm, evidence-led perspective to complex decision-making.

As his career has progressed, his focus has increasingly shifted toward governance, mentorship, and long-term value creation. He engages selectively with founders, boards, and investors where experience and judgement can be additive, particularly in regulated medtech, diagnostics, and life-science businesses navigating scale or transition.